Wilson Therapeutics starts Phase III of WTX101 for Wilson's disease

Wilson Therapeutics AB (SSE:WTX) began the Phase III FOCuS trial of decuprate bis-choline tetrathiomolybdate (WTX101) to treat Wilson's disease in patients

Read the full 211 word article

User Sign In